STME — what changed in the latest 10-Q
A section-by-section comparison of STME's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-04-10 vs the prior 10-Q · 2026-01-15
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +26 | −26 | ~7 | 7 |
| Controls & procedures | Text added/removed | 0 | 0 | ~2 | 1 |
| Risk factors | No material changes reported (points to the 10-K) | — | — | — | — |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Not shown (absent or not faithfully extractable): Market risk (Item 3), Legal proceedings, Other information
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-04-10
Effective November 1, 2024, the Company completed a 1-for-15 reverse split (the “Reverse Split”) of its common stock. All share and per-share amounts in this Quarterly Report on Form 10-Q have been retrospectively adjusted.
Results of Operations for the Three and Nine Months ended February 28, 2026 and 2025
Operating results for the three and nine months ended February 28, 2026 and 2025, and the changes in the operating results between those periods are summarized in the table below.
The Company did not have any revenue-generating activities during the three and nine months ended February 28, 2026 and 2025.
During the three months ended February 28, 2026, the Company’s operating expenses decreased by 45.1% from $131,086 the Company incurred during the three months ended February 28, 2025, to $71,908 incurred during the three months ended February 28, 2026. The largest change was associated with a $71,6…
Text removed vs the prior filing · source: 10-Q · 2026-01-15
Effective November 1, 2024, the Company completed a 1-for-15 reverse split (the “Reverse Split”) of its common stock. As a result of the Reverse Split, the Company’s authorized capital was decreased from 7,500,000,000 shares of common stock with par value of $0.001, of which 297,236,373 shares were …
ganglia (DRG) neurons under controlled conditions. Replicates will ensure robust statistical analysis, with a comprehensive report provided at the study's conclusion.
Results of Operations for the Three and Six Months ended November 30, 2025 and 2024
Operating results for the three and six months ended November 30, 2025 and 2024, and the changes in the operating results between those periods are summarized in the table below.
The Company did not have any revenue-generating activities during the three and six months ended November 30, 2025 and 2024.
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice